1. Home
  2. BIIB
  3. BIIB News

Latest Biogen Inc. (BIIB) News on February 22, 2025

Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
BIIB

Pharmaceutical Technology

3 days ago

Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment

We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative
BIIB

Simply Wall St.

3 days ago

We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
BIIB

Benzinga

4 days ago

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal

BIIB

MT Newswires

4 days ago

Bernstein Adjusts Price Target on Biogen to $159 From $160, Keeps Market Perform Rating

BIIB

MT Newswires

4 days ago

Piper Sandler Adjusts Price Target on Biogen to $135 From $138, Keeps Neutral Rating

BIIB

MT Newswires

4 days ago

Biogen, Stoke Partner on Dravet Syndrome Investigational Drug Zorevunersen

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
BIIB

Business Wire

4 days ago

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Biogen buys rights to Stoke’s rare epilepsy drug
BIIB

BioPharma Dive

4 days ago

Biogen buys rights to Stoke’s rare epilepsy drug

BIIB

MT Newswires

8 days ago

Guggenheim Cuts Biogen Price Target to $168 From $190

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
BIIB

Benzinga

9 days ago

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts

BIIB

MT Newswires

9 days ago

Biogen Still Offering Value, RBC Says

Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance
BIIB

Zacks

9 days ago

Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance

Sage Therapeutics price target lowered to $12 from $14 at Scotiabank
BIIB

TipRanks

9 days ago

Sage Therapeutics price target lowered to $12 from $14 at Scotiabank

Neumora shakes up its C-suite; Biogen cuts early-stage pipeline
BIIB

BioPharma Dive

9 days ago

Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

BIIB

MT Newswires

9 days ago

Truist Securities Adjusts Price Target on Biogen to $210 From $220, Keeps Buy Rating

BIIB

MT Newswires

9 days ago

Scotiabank Adjusts Biogen Price Target to $224 From $244

BIIB

MT Newswires

9 days ago

Wedbush Adjusts Biogen Price Target to $135 From $166

Biogen expects 2025 profit decline despite strong Q4
BIIB

Yahoo Finance Video

10 days ago

Biogen expects 2025 profit decline despite strong Q4

Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma
BIIB

Benzinga

10 days ago

Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma

BIIB

MT Newswires

10 days ago

Royalty Pharma to Provide up to $250 Million to Biogen for Litifilimab R&D

Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates
BIIB

Zacks

10 days ago

Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates

Biogen’s (NASDAQ:BIIB) Q4 Sales Top Estimates
BIIB

StockStory

10 days ago

Biogen’s (NASDAQ:BIIB) Q4 Sales Top Estimates

BIIB

MT Newswires

10 days ago

Biogen's Q4 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Set

Biogen expects lower 2025 profit as multiple sclerosis drugs face fierce competition
BIIB

Reuters

10 days ago

Biogen expects lower 2025 profit as multiple sclerosis drugs face fierce competition

Why Investors Might Hammer Biogen Despite Its Earnings Beat
BIIB

Investor's Business Daily

10 days ago

Why Investors Might Hammer Biogen Despite Its Earnings Beat

BIIB

Investing.com

11 days ago

Bernstein starts Biogen at ‘market-perform,’ notes near term uncertainty

Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
BIIB

StockStory

11 days ago

Biogen (BIIB) Reports Earnings Tomorrow: What To Expect

BIIB

MT Newswires

11 days ago

Bernstein Initiates Biogen at Market Perform With $160 Price Target

Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
BIIB

Zacks

12 days ago

Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?

Why Biogen Inc. (BIIB) Is Among the Best Healthcare Stocks To Buy According to Analysts
BIIB

Insider Monkey

14 days ago

Why Biogen Inc. (BIIB) Is Among the Best Healthcare Stocks To Buy According to Analysts

Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
BIIB

Zacks

15 days ago

Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Genentech eyes lupus market for Gazyva with positive Phase III data readout
BIIB

Pharmaceutical Technology

15 days ago

Genentech eyes lupus market for Gazyva with positive Phase III data readout

Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
BIIB

Zacks

17 days ago

Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth

Lilly’s investigational Alzheimer’s to be investigated in prevention trial
BIIB

Clinical Trials Arena

17 days ago

Lilly’s investigational Alzheimer’s to be investigated in prevention trial

Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
BIIB

Zacks

19 days ago

Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug

Why Are Analysts Bullish on Biogen Inc. (BIIB) Now?
BIIB

Insider Monkey

20 days ago

Why Are Analysts Bullish on Biogen Inc. (BIIB) Now?

BIIB

MT Newswires

22 days ago

Biogen, Eisai Say EU Panel Set to Discuss Additional Safety Data on Lecanemab

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
BIIB

GlobeNewswire

22 days ago

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics
BIIB

Zacks

23 days ago

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
BIIB

Zacks

24 days ago

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
BIIB

Zacks

24 days ago

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

BIIB

MT Newswires

24 days ago

BMO Capital Adjusts Price Target on Biogen to $156 From $164, Keeps Market Perform Rating

BIIB

MT Newswires

24 days ago

Leerink Partners Adjusts Biogen Price Target to $260 From $290, Maintains Outperform Rating

SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
BIIB

Zacks

25 days ago

SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up

Sage rejects Biogen’s $469m takeover bid
BIIB

Pharmaceutical Technology

25 days ago

Sage rejects Biogen’s $469m takeover bid

BIIB

MT Newswires

25 days ago

Citigroup Adjusts Price Target on Biogen to $160 From $190, Maintains Neutral Rating

BIIB

MT Newswires

a month ago

Sector Update: Health Care Stocks Gain Late Afternoon

BIIB

MT Newswires

a month ago

Sector Update: Health Care Stocks Gain Monday Afternoon

Sage rebuffs Biogen bid to take it over
BIIB

BioPharma Dive

a month ago

Sage rebuffs Biogen bid to take it over

BIIB

MT Newswires

a month ago

Update: Sage Therapeutics Board Rejects Biogen's Unsolicited Acquisition Bid

BIIB

MT Newswires

a month ago

SAGE Therapeutics Board Rejects Biogen's Unsolicited Acquisition Bid

Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
BIIB

Reuters

a month ago

Sage rejects Biogen's $469 million takeover offer, says offer undervalues company

Eisai and Biogen’s LEQEMBI sBLA set for Alzheimer’s maintenance dosing
BIIB

Pharmaceutical Technology

a month ago

Eisai and Biogen’s LEQEMBI sBLA set for Alzheimer’s maintenance dosing

BIIB

MT Newswires

a month ago

Goldman Sachs Adjusts Price Target on Biogen to $281 From $290, Keeps Buy Rating

BIIB

MT Newswires

a month ago

Biogen, Eisai Receive US FDA Biologics Approval for Leqembi Dosing

US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
BIIB

Reuters

a month ago

US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
BIIB

GlobeNewswire

a month ago

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug
BIIB

Zacks

a month ago

FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug

Biogen’s higher dose Spinraza under review by US and EU regulators
BIIB

Pharmaceutical Technology

a month ago

Biogen’s higher dose Spinraza under review by US and EU regulators

BIIB

MT Newswires

a month ago

Biogen Gets FDA, EMA Approval to Study Higher Dose Regimen of Spinal Muscular Atrophy Treatment

BIIB

MT Newswires

a month ago

Wedbush Cuts Price Target on Biogen to $166 From $187, Keeps Neutral Rating

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
BIIB

GlobeNewswire

a month ago

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk
BIIB

Yahoo Finance

a month ago

Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk

Bain Capital in Talks to Buy Mitsubishi Tanabe Pharma
BIIB

The Wall Street Journal

a month ago

Bain Capital in Talks to Buy Mitsubishi Tanabe Pharma

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
BIIB

Zacks

a month ago

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

Eli Lilly Stock Has Tumbled 22% Since Its August High. Is It A Buy Or A Sell?
BIIB

Investor's Business Daily

a month ago

Eli Lilly Stock Has Tumbled 22% Since Its August High. Is It A Buy Or A Sell?

At JPM, Biogen CEO tries to take down the deal temperature
BIIB

BioPharma Dive

a month ago

At JPM, Biogen CEO tries to take down the deal temperature

Federal watchdog cites concerns with FDA’s accelerated approval process
BIIB

BioPharma Dive

a month ago

Federal watchdog cites concerns with FDA’s accelerated approval process

Biogen CEO sees no burning need for more acquisitions
BIIB

Reuters

a month ago

Biogen CEO sees no burning need for more acquisitions

Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist
BIIB

TipRanks

a month ago

Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist

Biogen bid for Sage does not change narrative, says BMO Capital
BIIB

TipRanks

a month ago

Biogen bid for Sage does not change narrative, says BMO Capital

FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
BIIB

Benzinga

a month ago

FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi

Eisai and Biogen’s subcutaneous Leqembi set for FDA review
BIIB

Pharmaceutical Technology

a month ago

Eisai and Biogen’s subcutaneous Leqembi set for FDA review

BIIB

MT Newswires

a month ago

Biogen, Eisai Say Biologics License Application for Leqembi Accepted by US FDA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
BIIB

GlobeNewswire

a month ago

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Biogen proposes acquisition of partner Sage Therapeutics
BIIB

Pharmaceutical Technology

a month ago

Biogen proposes acquisition of partner Sage Therapeutics

Biogen Offers to Buy Remaining Stake in Sage Therapeutics
BIIB

Zacks

a month ago

Biogen Offers to Buy Remaining Stake in Sage Therapeutics

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
BIIB

Benzinga

a month ago

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen
BIIB

Barrons.com

a month ago

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen

BIIB

MT Newswires

a month ago

SAGE Therapeutics Receives Unsolicited $7.22 Per Share Acquisition Proposal From Biogen

Biogen proposes to buy remaining stake in Sage in $442 million deal
BIIB

Reuters

a month ago

Biogen proposes to buy remaining stake in Sage in $442 million deal

BIIB

MT Newswires

a month ago

Wells Fargo Cuts Price Target on Biogen to $165 From $190, Maintains Equalweight Rating

Here’s Why ClearBridge Growth Strategy Sold Biogen (BIIB)
BIIB

Insider Monkey

a month ago

Here’s Why ClearBridge Growth Strategy Sold Biogen (BIIB)

Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets
BIIB

BioPharma Dive

a month ago

Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets

Alzheimer’s Drugs Eyed as Next Big Obesity-Like Opportunity
BIIB

Bloomberg

a month ago

Alzheimer’s Drugs Eyed as Next Big Obesity-Like Opportunity

Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?
BIIB

Insider Monkey

a month ago

Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?

BIIB

MT Newswires

a month ago

Truist Cuts Price Target on Biogen to $220 From $302, Keeps Buy Rating

BIIB

MT Newswires

a month ago

RBC Cuts Price Target on Biogen to $231 From $260, Keeps Outperform Rating

These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
BIIB

Motley Fool

2 months ago

These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024

BIIB

MT Newswires

2 months ago

Guggenheim Adjusts Price Target on Biogen to $190 From $245, Maintains Buy Rating

BIIB

MT Newswires

2 months ago

Biogen Shares Lower After Piper Sandler Downgrade

BIIB

Investing.com

2 months ago

Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges

BIIB

MT Newswires

2 months ago

Piper Sandler Downgrades Biogen to Neutral From Overweight

Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
BIIB

Zacks

2 months ago

Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term

The 5 worst performing stocks on the Nasdaq 100 in 2024
BIIB

TheStreet

2 months ago

The 5 worst performing stocks on the Nasdaq 100 in 2024

Biogen Inc. (BIIB): Among the Cheap Healthcare Stocks to Buy Heading Into 2025
BIIB

Insider Monkey

2 months ago

Biogen Inc. (BIIB): Among the Cheap Healthcare Stocks to Buy Heading Into 2025

Biogen Faces Multiple Analyst Downgrades in December 2024
BIIB

GuruFocus.com

2 months ago

Biogen Faces Multiple Analyst Downgrades in December 2024

BIIB

Investing.com

2 months ago

BMO cuts rating on Merck and Biogen, on lack of near term catalyst

BIIB

MT Newswires

2 months ago

BMO Capital Downgrades Biogen to Market Perform From Outperform, Adjusts Price Target to $164 From $230

BIIB

Investing.com

2 months ago

Stifel downgrades Biogen on slow Alzheimer’s drug launch, uncertainty ahead

Share on Social Networks: